AGGF1
Reaktivität: Human
WB, IHC
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
Optimal working dilution should be determined by the investigator.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
0.1 mg/mL
Buffer
PBS, 0.02 % sodium azide, 0.1 % bovine serum albumin
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
4 °C
Informationen zur Lagerung
Store at 2 - 8 °C.
Target
AGGF1
(Angiogenic Factor with G Patch and FHA Domains 1 (AGGF1))
Andere Bezeichnung
AGGF1 / VG5Q
Hintergrund
VG5Q functions as an angiogenic factor in promoting angiogenesis and suppression of VG5Q expression inhibits vessel formation. Angiogenic factors are critical to the initiation of angiogenesis and maintenance of the vascular network. Angiogenesis has an essential role in pathological conditions such as cancer and various ischaemic and inflammatory diseases. VG5Q can bind to endothelial cells and promote cell proliferation, suggesting that the protein may act in an autocrine fashion. VG5Q interacts with TWEAK (also known as TNFSF12), another secreted angiogenic factor. VG5Q shows strong expression in blood vessels and is secreted when vessel formation is initiated. VG5Q protein was detected mostly in the cytoplasm and around the nuclei of human microvascular endothelial cells (HMVECs). Furthermore VG5Q is detected in human umbilical vein endothelial cells (HUVECs), human heart fibroblast (HHF) and ovarian cancer cells (OV-3), but low expression was detected in kidney cancer cells (RP-45), HeLa Cells and bladder cancer cells.Synonyms: Angiogenic factor VG5Q, Angiogenic factor with G patch and FHA domains 1, G patch domain-containing protein 7, GPATC7, GPATCH7, Vasculogenesis gene on 5q protein